Med Safety

{
  "active_ingredients": [
    {
      "name": "WARFARIN SODIUM",
      "strengths": [
        "1 mg/1",
        "10 mg/1",
        "2 mg/1",
        "2.5 mg/1",
        "3 mg/1",
        "4 mg/1",
        "5 mg/1",
        "6 mg/1",
        "7.5 mg/1"
      ]
    }
  ],
  "adverse_events": {
    "note": "FAERS reports naming the drug as suspect or concomitant; a report does not establish that the drug caused the reaction",
    "reports": 135508,
    "serious": 108360,
    "serious_share": 0.8,
    "top_reactions": [
      {
        "reaction": "INTERNATIONAL NORMALISED RATIO INCREASED",
        "reports": 11252
      },
      {
        "reaction": "DYSPNOEA",
        "reports": 8965
      },
      {
        "reaction": "DRUG INTERACTION",
        "reports": 6779
      }
    ]
  },
  "alerts": [
    "the label carries a boxed warning"
  ],
  "data_as_of": {
    "adverse_events": "2026-07-30",
    "label": "2026-10-23",
    "ndc": "2026-10-23",
    "recalls": "2026-10-14",
    "shortages": null
  },
  "drug": "warfarin",
  "issues": [
    "74 labels match \"warfarin\"; this is the most recent, from Coupler LLC, and other labelers' text may differ",
    "label sections shortened (contraindications, warnings, drug_interactions, adverse_reactions, pregnancy): the full text is at label.url",
    "active ingredients and forms are from 100 of 149 NDC products"
  ],
  "label": {
    "adverse_reactions": "The following serious adverse reactions to warfarin sodium are discussed in greater detail in other sections of the labeling: Hemorrhage [see Boxed Warning , Warnings and Precautions (5.1) …",
    "ask_a_doctor": null,
    "boxed_warning": "WARNING: BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [see Warnings and Precautions (5.1) ] . Perform regular monitoring of INR in all treated patients [see Dosage and Administration (2.1) ] . …",
    "brand_names": [
      "Warfarin Sodium"
    ],
    "contraindications": "Warfarin sodium is contraindicated in: Pregnancy Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism …",
    "drug_interactions": "Concomitant use of drugs that increase bleeding risk, antibiotics, antifungals, botanical (herbal) products, and inhibitors and inducers of CYP2C9, 1A2, or 3A4. ( 7 ) …",
    "effective_date": "2026-08-31",
    "generic_names": [
      "WARFARIN"
    ],
    "has_boxed_warning": true,
    "indications": "Warfarin sodium tablets are indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE). …",
    "labels_matching": 74,
    "manufacturer": "Coupler LLC",
    "pharmacologic_class": [],
    "pregnancy": "Pregnant women with mechanical heart valves: warfarin sodium may cause fetal harm; however, the benefits may outweigh the risks. ( 8.1 ) …",
    "product_type": "HUMAN PRESCRIPTION DRUG",
    "recent_major_changes": null,
    "routes": [
      "ORAL"
    ],
    "rxcui": [
      "855312"
    ],
    "set_id": "5a5b5e3a-6556-a542-e063-6294a90a6d3f",
    "stop_use": null,
    "truncated": [
      "contraindications",
      "warnings",
      "drug_interactions",
      "adverse_reactions",
      "pregnancy"
    ],
    "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a5b5e3a-6556-a542-e063-6294a90a6d3f",
    "version": "1",
    "warnings": "Tissue necrosis: Necrosis or gangrene of skin or other tissues can occur, with severe cases requiring debridement or amputation. …"
  },
  "products": {
    "brand_names": [
      "Jantoven",
      "Warfarin Sodium"
    ],
    "combinations": 0,
    "counted": 100,
    "dea_schedules": [],
    "dosage_forms": [
      "TABLET"
    ],
    "marketing_categories": [
      "ANDA"
    ],
    "ndc_products": 149,
    "routes": [
      "ORAL"
    ]
  },
  "recalls": {
    "counted": 9,
    "latest_report": "2024-01-03",
    "ongoing": 0,
    "ongoing_by_class": {
      "Class I": 0,
      "Class II": 0,
      "Class III": 0
    },
    "ongoing_recalls": [],
    "recent": [
      {
        "classification": "Class II",
        "code_info": "Batch 2323041",
        "distribution": "Nationwide USA",
        "firm": "CARDINAL HEALTHCARE",
        "initiated": "2022-01-26",
        "product": "Warfarin Sodium Tablets, USP, 5 mg, 100 Tablets per bottle, Rx Only, Manufactured for: Teva Pharmaceuticals, Parsippany, NJ 07054. NDC: 0093-1721-01",
        "reason": "CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.",
        "recall_number": "D-0201-2024",
        "reported": "2024-01-03",
        "status": "Terminated",
        "terminated": "2024-09-29",
        "voluntary_mandated": "Voluntary: Firm initiated"
      }
    ],
    "total": 9
  },
  "searched_as": [
    "warfarin"
  ],
  "shortage": {
    "current": 0,
    "limited": 0,
    "on_shortage_list": false,
    "presentations": 0,
    "reasons": [],
    "records": [],
    "status": null,
    "to_be_discontinued": 0,
    "unavailable": 0
  },
  "source": {
    "api_urls": [
      "https://api.fda.gov/drug/label.json?search=openfda.brand_name%3A%22warfarin%22+OR+openfda.generic_name%3A%22warfarin%22+OR+openfda.substance_name%3A%22warfarin%22&sort=effective_time%3Adesc&limit=10",
      "https://api.fda.gov/drug/shortages.json?search=openfda.brand_name%3A%22warfarin%22+OR+openfda.generic_name%3A%22warfarin%22+OR+generic_name%3A%22warfarin%22&limit=1000"
    ],
    "citation": "Source: openFDA, US Food and Drug Administration",
    "disclaimer": "openFDA: do not rely on openFDA to make decisions regarding medical care; assume all results are unvalidated",
    "licence": "public domain, CC0 1.0 (open.fda.gov/license)",
    "name": "openFDA (US Food and Drug Administration): drug label, NDC directory, drug shortages, enforcement reports, FAERS"
  }
}

# bash or zsh: see the payment challenge. Nothing is charged.
curl -sS -g -i -X POST 'https://jotowl.com/v1/med-safety' \
  -H 'content-type: application/json' \
  --data-raw '{"drug":"warfarin"}'

# x402 v2 sends the challenge base64-encoded in the PAYMENT-REQUIRED header (v1 sends it in the body).
# To read the header:
curl -sS -g -o /dev/null -D - -X POST 'https://jotowl.com/v1/med-safety' \
  -H 'content-type: application/json' \
  --data-raw '{"drug":"warfarin"}' \
  | grep -i '^payment-required:' | cut -d' ' -f2 | tr -d '\r' | base64 --decode

// npm i @x402/fetch @x402/evm viem
import { wrapFetchWithPayment, x402Client } from "@x402/fetch";
import { registerExactEvmScheme } from "@x402/evm/exact/client";
import { privateKeyToAccount } from "viem/accounts";

// Pays at most $0.004 per call.
const client = new x402Client().setSpendControls({ maxAmountPerPayment: "$0.004" });
registerExactEvmScheme(client, { signer: privateKeyToAccount(process.env.EVM_PRIVATE_KEY) });
const pay = wrapFetchWithPayment(fetch, client);

// Not sure it's safe to pay? ToolVet checks it first for $0.005. Pay for that from a separate
// client: this one is capped at $0.004 per payment. GET https://toolvet.app/api/v1/check?url=https%3A%2F%2Fjotowl.com%2Fv1%2Fmed-safety&method=POST
const res = await pay("https://jotowl.com/v1/med-safety", {
  method: "POST",
  headers: { "content-type": "application/json" },
  body: JSON.stringify({
    "drug": "warfarin"
  }),
});
console.log(res.status, await res.text());

# pip install "x402[requests,evm]"
import os
from eth_account import Account
from x402 import x402ClientSync
from x402.http.clients import x402_requests
from x402.mechanisms.evm import EthAccountSigner
from x402.mechanisms.evm.exact.register import register_exact_evm_client

# Pays at most $0.004 per call.
client = x402ClientSync().set_spend_controls({"max_amount_per_payment": "$0.004"})
register_exact_evm_client(client, EthAccountSigner(Account.from_key(os.environ["EVM_PRIVATE_KEY"])))

with x402_requests(client) as session:
    res = session.post(
        "https://jotowl.com/v1/med-safety",
        json={
            "drug": "warfarin",
        },
    )
    print(res.status_code, res.text)